SH2D3C and COVID-19: Given the urgent need for antiviral therapies for COVID-19 and the fact that the macrodomain is an attractive therapeutic target (9, 15, 16, 17), we attempted to repurpose compounds that already have regulatory approval as potential Nsp3 macrodomain inhibitors.